Antidiabetic Medications & The Nursing Process. Karen Ruffin RN, MSN Ed. Is it Diabetes or is it Hyperglycemia???????????????. Is there a difference and if so what is it??. What is ???????. Hyperglycemia Insulin The primary source of energy for our bodies. What is the difference between.
01 / 92Antidiabetic Medications & The Nursing Process
1 / 17
Télécharger la présentation
Antidiabetic Medications & The Nursing Process
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation
Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement.Téléchargez la présentation en cliquant sur ce lien.Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.
Criteria for Diagnosis of DMDM Screening • Symptoms of diabetes + casual plasma glucose level less than or equal to 200 mg/dL OR • Fasting plasma glucose higher than or equal to 126 mg/dL OR • 2-hour postload glucose level higher than or equal to 200 mg/dL during an oral glucose tolerance test • Impaired glucose tolerance (IGT) • FPG <110 mg/dL: normal fasting glucose • FPG ≥110 mg/dL but <126 mg/dL: impaired fasting glucose (IFG) • FPG ≥126 mg/dL: provisional diagnosis of diabetes mellitus
What is a HbA1c? • It is a test that allows healthcare providers to see how diabetics have managed their blood glucose level over the last 2-3 months…. • Why do you think this is important????
Type 1 Diabetes • Lack of insulin production OR • Production of defective insulin • Affected patients need exogenous insulin • Complications • Diabetic ketoacidosis (DKA) • Hyperosmolarnonketotic syndrome • Oral antidiabetic drugs not effective
Type 2 Diabetes • Most common type • Caused by insulin deficiency and insulin resistance • Many tissues are resistant to insulin • Reduced number insulin receptors • Insulin receptors less responsive • These people respond to oral hypoglycemics
Type 2 Diabetes • Several comorbid conditions • metabolic syndrome OR insulin-resistance syndrome OR syndrome X • Obesity • Coronary artery disease • Dyslipidemia • Hypertension • Microalbuminemia (protein in the urine) • Enhanced conditions for embolic events (blood clots) • Insulin Resistance
Treatment DIfferences • Type 1 • Exogenous insulin • Dietary control • Type 2 • Lifestyle changes • Dietary control • Weight reduction • Exercise • May require oral hypoglycemic therapy or exogenous insulin • Insulin when oral hypoglycemic medications can no longer provide glycemic control
Gestational Diabetes • Hyperglycemia that develops during pregnancy • Insulin must be given to prevent birth defects • 4% of all pregnancies • Must be reclassified if it persists 6 weeks post-delivery • Usually subsides after delivery • 30% of patients may develop Type 2 DM within 10 to 15 years
Indications for Oral Hypoglycemics • They are used to lower blood sugar levels in patients that diet and exercise have failed. • The patient must have some pancreatic function left. • They can be used as a monotherapy or in conjunction with other oral hypoglycemics.
Contraindications • Know drug allergy • Active hypoglycemia • Usually not used during pregnancy subq insulin's are used then. • Liver disease • Kidney disease • Depending on the metabolic pathways of the medication
Sulfonylureas • Stimulate insulin secretion from the beta cells of the pancreas, thus increasing insulin levels • Beta cell function must be present • Improve sensitivity to insulin in tissues • Result: lower blood glucose levels • First-generation drugs not used as frequently now
Interactions • Sulfonylureas • Hypoglycemic effect increases when taken with alcohol, anabolic steroids, many other drugs • Adrenergics (beta blockers) may mask many of the symptoms of hypoglycemia • Hyperglycemia: corticosteroids, phenothiazines, diuretics, oral contraceptives, thyroid replacement hormones, phenytoin, diazoxide and lithium. • Allergic cross-sensitivity may occur with loop diuretics and sulfonamide antibiotics • May interact with alcohol/OTC medication containing alcohol) - causing a disulfiram (Antabuse) -type reaction (facial flushing, pounding headache, feeling of breathlessness, and nausea)
Meglitinides • Meglitinides • repaglinide (Prandin) • nateglinide (Starlix) • Meglitinides • Action similar to sulfonylureas • Increase insulin secretion from the pancreas
Biguanides • Biguanides • metformin (Glucophage) • Biguanides • Decrease production of glucose • Increase uptake of glucose by tissues • Does not increase insulin secretion from the pancreas (does not cause hypoglycemia)
Adverse Effects • Metformin • Primarily affects GI tract: abdominal bloating, nausea, cramping, diarrhea, feeling of fullness • May also cause metallic taste, reduced vitamin B12 levels • Lactic acidosis is rare but lethal if it occurs • Does not cause hypoglycemia
Thiazolidinediones • Thiazolidinediones • pioglitazone (Actos), • rosiglitazone (Avandia) • Also known as “glitazones” • Thiazolidinediones • Decrease insulin resistance • “Insulin sensitizing drugs” • Increase glucose uptake and use in skeletal muscle • Inhibit glucose and triglyceride production in the liver
Adverse Effects • Thiazolidinediones • Moderate weight gain • Edema • Mild anemia • Hepatic toxicity—monitor liver function tests
Alpha-glucosidase Inhibitors • Alpha-glucosidase inhibitors • acarbose (Precose) • miglitol (Glyset) • Alpha-glucosidase inhibitors • Reversibly inhibit the enzyme alpha-glucosidase in the small intestine • Result: delayed absorption of glucose • Must be taken with meals to prevent excessive postprandial blood glucose elevations (with the “first bite” of a meal)
Adverse Effects • α-glucosidase inhibitors • Flatulence • diarrhea • abdominal pain • Do not cause hypoglycemia, hyperinsulinemia, or weight gain
Insulins • Mechanism of Action • Substitute for & same effects as endogenous insulin • Restores the diabetic patient’s ability to: • Metabolize carbohydrates, fats, and proteins • Store glucose in the liver • Convert glycogen to fat stores • Some derived from porcine sources • Most now human-derived, using recombinant DNA technologies • Goal: tight glucose control • To reduce the incidence of long-term complications
Indications • To treat both types of diabetes • Each patient requires careful customization of the dosing regimen for optimal glycemic control